ACMA To Offer Board Certification Program for Biologics and Biosimilars
The Accreditation Council for Medical Affairs (ACMA) announced that it will launch a new Board Certification program focused on biologics and biosimilars in November 2022. The Board Certified Biologics and Biosimilars Specialist (BCBBS) program will be for healthcare professionals (e.g., pharmacists, prescribers, PhDs, Industry/MSLs etc.) with the goal of creating a new industry standard for effective management of biologics.
Read more about the new program here.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
